LUMIRABIO 药光生物
EN
English简体中文
Investigational
Qualified institutional review only

Retatrutide remains investigational and is not approved for public use. Technical and supply discussions are limited to qualified institutions and the requirements applicable to the target market.

Last reviewed: August 21, 2026 · Content owner: LUMIRABIO Technical Content Team

Peptide APIs & Raw Materials / Retatrutide

Investigational acylated peptide

Investigational

Retatrutide API Raw Material for Qualified B2B Programs

Retatrutide is an investigational single peptide with agonist activity at the GIP, GLP-1, and glucagon receptors. It remains under clinical development; this page supports qualified institutional review of reference identity, proposed supplied form, documentation, destination, and project eligibility only.

Request a technical dossier review

Institutional B2B requests only. The team reviews organization, intended use, market and disclosure rights. Submission is not qualification, a supply commitment or automatic CoA access. Retatrutide requests are limited to qualified institutional research and development review.

Do not include patient, personal-use, medical or confidential project information.

Documents are shared only after qualification and disclosure approval.

Review molecular identity

The formula, molecular weight, sequence description, and public structure source establish the reference molecular identity; the proposed supplied form and corresponding CAS are defined in the formal specification.

Reference molecular structureRetatrutide two-dimensional molecular structure
Formula
C221H342N46O68
CAS
Confirm exact form
Average MW
Approximately 4731 g/mol

Product introduction

Retatrutide is an investigational single peptide with agonist activity at the GIP, GLP-1, and glucagon receptors. It is not a DPP-4 inhibitor and remains under clinical development. The technical package brings together peptide API raw material reference identity, proposed form, analytical documentation, destination, and project eligibility for qualified institutional review.

Retatrutide peptide API raw material reference sheet
Product reference sheet with molecular identity, specification, process, and structure information.

Reference identity

Product parameters

Public identity fields organize the first review. Formal specifications and batch records govern the proposed supplied material.

Reference identity and review scope, not a batch release certificate.
ParameterReference / specificationSource and scope
Product nameRetatrutideInvestigational; qualified institutional review only
CASConfirm exact formNamed reference identity; formal documents govern the supplied material
FormulaC221H342N46O68PubChem reference structure; supplied form not established
Not a batch measurement; counter-ion and supplied form require confirmation
Average MWApproximately 4731 g/mol
Peptide class39-residue peptide backboneReference sequence identity
Portfolio specification≥99% by HPLCBatch-specific result and applicable method per CoA
Single impurity / storageConfirm for the specification and batchNo universal limit or storage-temperature guarantee

Sequence / structure 39-residue synthetic peptide backbone with non-standard residues and a C20 fatty-diacid side-chain modification.

Material definition

The formula, molecular weight, sequence description, and public structure source establish the reference molecular identity; the proposed supplied form and corresponding CAS are defined in the formal specification.

Peptide API packaging prepared for qualified supply review
Peptide API packaging and supply presentation.

Packaging and supply handoff

Confirm the supplied form before planning the shipment.

Packaging, storage, documents, eligible U.S. warehouse pathway, destination, and timing are aligned only after the product and batch scope is clear.

  1. 01

    Supplied form

    Confirm counter-ion, grade, packaging configuration, and storage conditions.

  2. 02

    Document handoff

    Match specification, CoA, analytical support, and shipping records to the proposed batch.

  3. 03

    Regional pathway

    Review Los Angeles or New Jersey eligibility; stock, route, release, and timing remain order-specific.